Xiao-Li Lu1, Si-Sun Liu2, Zhen-Fang Xiong2, Fen Wang2, Xia-Ying Li1, Huan Deng3. 1. Sanxiang Hospital Zhongshan, China. 2. The First Affiliated Hospital of Nanchang University Nanchang, China. 3. Department of Pathology, The Fourth Affiliated Hospital of Nanchang University Nanchang, China.
Abstract
AIM: The underlying mechanisms of chemoresistance-induced recurrence of ovarian carcinoma are largely unknown. The purpose of this study was to investigate the clinical significance of RAD51C and its role in ovarian tumorigenesis and progression. METHODS: 60 cases of ovarian epithelial tumors (30 benign and 30 malignant tumors, respectively) were enrolled from 2014 to 2016. Immunohistochemistry was used to evaluate RAD51C expression in tumor tissues, and RT-PCR was employed to test RAD51C mRNA levels in SKOV3, A2780, and CAOV3 cell lines. Targeted knockdown of RAD51C was achieved with siRNA to explore the changes of cell proliferation, migration, and apoptosis. RESULTS: RAD51C protein level in carcinoma tissues, especially in the high-grade group (P<0.001), was significantly higher than that of benign tumors and associated with pathological type, stage, and overall survival (P<0.05). Downregulation of RAD51C promoted apoptosis and decreased cell survival rate and migration. CONCLUSIONS: Our results supported that RAD51C contributes to the progression of ovarian carcinoma, suggesting its promising application as an independent prognostic marker for diagnosis and treatment. IJCEP
AIM: The underlying mechanisms of chemoresistance-induced recurrence of ovarian carcinoma are largely unknown. The purpose of this study was to investigate the clinical significance of RAD51C and its role in ovarian tumorigenesis and progression. METHODS: 60 cases of ovarian epithelial tumors (30 benign and 30 malignant tumors, respectively) were enrolled from 2014 to 2016. Immunohistochemistry was used to evaluate RAD51C expression in tumor tissues, and RT-PCR was employed to test RAD51C mRNA levels in SKOV3, A2780, and CAOV3 cell lines. Targeted knockdown of RAD51C was achieved with siRNA to explore the changes of cell proliferation, migration, and apoptosis. RESULTS:RAD51C protein level in carcinoma tissues, especially in the high-grade group (P<0.001), was significantly higher than that of benign tumors and associated with pathological type, stage, and overall survival (P<0.05). Downregulation of RAD51C promoted apoptosis and decreased cell survival rate and migration. CONCLUSIONS: Our results supported that RAD51C contributes to the progression of ovarian carcinoma, suggesting its promising application as an independent prognostic marker for diagnosis and treatment. IJCEP
Authors: Elisena Franzese; Sara Centonze; Anna Diana; Francesca Carlino; Luigi Pio Guerrera; Marilena Di Napoli; Ferdinando De Vita; Sandro Pignata; Fortunato Ciardiello; Michele Orditura Journal: Cancer Treat Rev Date: 2018-12-04 Impact factor: 12.111
Authors: Chao Yin; Monika Kulasekaran; Tina Roy; Brennan Decker; Sonja Alexander; Mathew Margolis; Reena C Jha; Gary M Kupfer; Aiwu R He Journal: Cancers (Basel) Date: 2022-05-23 Impact factor: 6.575